Home LiteratureArticle Details
PMID: 19147828 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues.

The American journal of pathology ·Vol. 174 ·No. 2 ·2009-02-00 ·Pages 661-70

Martelli MP, Sozzi G, Hernandez L, Pettirossi V, Navarro A, Conte D, Gasparini P, Perrone F, Modena P, Pastorino U, Carbone A, Fabbri A, Sidoni A, Nakamura S, Gambacorta M, Fernández PL, Ramirez J, Chan JK, Grigioni WF, Campo E, Pileri SA, Falini B

Abstract

A fusion gene, echinoderm microtubule associated protein like 4-anaplastic lymphoma kinase (EML4-ALK), with transforming activity has recently been identified in a subset of non-small cell lung cancer (NSCLC), but its pathogenetic, diagnostic, and therapeutic roles remain unclear. Both frequency and type of EML4-ALK transcripts were investigated by reverse transcription PCR in 120 frozen NSCLC specimens from Italy and Spain; non-neoplastic lung tissues taken far from the tumor were used as controls. In cases carrying the fusion transcript, we determined EML4-ALK gene and protein levels using fluorescence in situ hybridization, Western blotting, and immunoprecipitation. We also analyzed ALK protein levels in paraffin samples from 662 NSCLC specimens, including the 120 cases investigated in the molecular studies. EML4-ALK transcripts (variants 1 and 3) were detected in 9 of 120 NSCLC samples but were not specific for NSCLC since they were also found in non-cancerous lung tissues taken far from the tumor. Notably, no transcripts were detected in matching tumor samples from these patients. Fluorescence in situ hybridization analysis of cases expressing EML4-ALK transcripts showed that only a minority of cells harbored the EML4-ALK gene. None of these cases was found to express the EML4-ALK protein as examined by immunohistochemistry, Western blotting, and immunoprecipitation. The EML4-ALK transcript cannot be regarded as a specific diagnostic tool for NSCLC. Our results show therefore that the causal role and value of EML4-ALK as a therapeutic target remain to be defined.

MeSH Terms
Aged Aged, 80 and over Biomarkers, Tumor/analysis Blotting, Western Carcinoma, Non-Small-Cell Lung/genetics,metabolism Female Gene Rearrangement Humans Immunohistochemistry Immunoprecipitation In Situ Hybridization, Fluorescence Lung/metabolism Lung Neoplasms/genetics,metabolism Male Middle Aged Oncogene Proteins, Fusion/biosynthesis,genetics Reverse Transcriptase Polymerase Chain Reaction Transcription, Genetic
Chemicals
Biomarkers, Tumor EML4-ALK fusion protein, human Oncogene Proteins, Fusion
Authors & Affiliations
22 authors, click to expand affiliations / ORCID
Martelli Maria Paola
Institute of Hematology, University of Perugia, Perugia, Italy.
Sozzi Gabriella
Hernandez Luis
Pettirossi Valentina
Navarro Alba
Conte Davide
Gasparini Patrizia
Perrone Federica
Modena Piergiorgio
Pastorino Ugo
Carbone Antonino
Fabbri Alessandra
Sidoni Angelo
Nakamura Shigeo
Gambacorta Marcello
Fernández Pedro Luis
Ramirez Jose
Chan John K C
Grigioni Walter Franco
Campo Elias
Pileri Stefano A
Falini Brunangelo
References (34)
34 references, click to expand
  1. EML4-ALK fusion lung cancer: a rare acquired event.
    Neoplasia. 2008 Mar;10(3):298-302 PMID: 18320074
  2. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1.
    Blood. 1997 Feb 15;89(4):1394-404 PMID: 9028963
  3. Characterization of t(2;5) reciprocal transcripts and genomic breakpoints in CD30+ cutaneous lymphoproliferations.
    Blood. 1998 Jun 15;91(12):4668-76 PMID: 9616164
  4. EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers.
    Br J Cancer. 2008 May 6;98(9):1536-9 PMID: 18414414
  5. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation.
    Blood. 1997 Mar 1;89(5):1483-90 PMID: 9057627
  6. Pathobiology of ALK+ anaplastic large-cell lymphoma.
    Blood. 2007 Oct 1;110(7):2259-67 PMID: 17519389
  7. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors.
    Am J Pathol. 2000 Aug;157(2):377-84 PMID: 10934142
  8. Echinoderm microtubule-associated protein like protein 4, a member of the echinoderm microtubule-associated protein family, stabilizes microtubules.
    Neuroscience. 2007 Feb 23;144(4):1373-82 PMID: 17196341
  9. Cancer statistics, 2006.
    CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 PMID: 16514137
  10. A mouse model for EML4-ALK-positive lung cancer.
    Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19893-7 PMID: 19064915
  11. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.
    Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):270-5 PMID: 17185414
  12. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.
    Blood. 2000 Dec 1;96(12):3681-95 PMID: 11090048
  13. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.
    Cancer Res. 2008 May 1;68(9):3389-95 PMID: 18451166
  14. Human EML4, a novel member of the EMAP family, is essential for microtubule formation.
    Exp Cell Res. 2006 Oct 15;312(17):3241-51 PMID: 16890222
  15. Genomic approaches to lung cancer.
    Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4384s-4391s PMID: 16857815
  16. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.
    Cell. 2007 Dec 14;131(6):1190-203 PMID: 18083107
  17. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK.
    Blood. 1999 Nov 15;94(10):3509-15 PMID: 10552961
  18. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.
    Clin Cancer Res. 2008 Jul 1;14(13):4275-83 PMID: 18594010
  19. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
    J Thorac Oncol. 2008 Jan;3(1):13-7 PMID: 18166835
  20. Biochemical detection of novel anaplastic lymphoma kinase proteins in tissue sections of anaplastic large cell lymphoma.
    Am J Pathol. 1999 Jun;154(6):1657-63 PMID: 10362790
  21. ALK+ lymphoma: clinico-pathological findings and outcome.
    Blood. 1999 Apr 15;93(8):2697-706 PMID: 10194450
  22. Cancer: broken genes in solid tumours.
    Nature. 2007 Aug 2;448(7153):545-6 PMID: 17671492
  23. ALK is not expressed in Hodgkin disease.
    Blood. 2001 Mar 15;97(6):1901-2 PMID: 11263444
  24. ALK is a novel dependence receptor: potential implications in development and cancer.
    Cell Cycle. 2007 Jul 1;6(13):1533-8 PMID: 17611412
  25. Large-cell anaplastic lymphoma-specific translocation (t[2;5] [p23;q35]) in Hodgkin's disease: indication of a common pathogenesis?
    Lancet. 1995 Jan 14;345(8942):87-90 PMID: 7815887
  26. Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry.
    Blood. 2002 Jan 15;99(2):409-26 PMID: 11781220
  27. ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum.
    Am J Pathol. 1998 Sep;153(3):875-86 PMID: 9736036
  28. ALK-positive lymphoma: a single disease with a broad spectrum of morphology.
    Blood. 1998 Mar 15;91(6):2076-84 PMID: 9490693
  29. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.
    Cancer Res. 2008 Jul 1;68(13):4971-6 PMID: 18593892
  30. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
    Nature. 2007 Aug 2;448(7153):561-6 PMID: 17625570
  31. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients.
    Cancer Res. 2005 Sep 1;65(17):7568-72 PMID: 16140919
  32. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
    N Engl J Med. 2004 May 20;350(21):2129-39 PMID: 15118073
  33. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.
    Science. 1994 Mar 4;263(5151):1281-4 PMID: 8122112
  34. EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas.
    Lung Cancer. 2008 Aug;61(2):163-9 PMID: 18242762
Article Info
Journal
The American journal of pathology
Abbr.
Am J Pathol
ISSN
1525-2191
Published
2009-02-00
Epub
2009-00-15
Pages
661-70
Language
English
Region
United States
NLM ID
0370502
PMCID
PMC2630573
Subset
IM
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com